The risk of developing bile duct cancer, also known as cholangiocarcinoma, is almost doubled for type 2 diabetics using one of the following diabetes medicines: Januvia (sitagliptin) Janumet (sitagliptin / metformin HCl) Onglyza (saxagliptin) Kombiglyze XR (saxagliptin and metformin) Qtern (dapagliflozin and saxagliptin) Nesina … [Read more...]
Lower Limbs Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects
New medical evidence indicates that lower limbs amputations may be a “drug-class” side effect for all of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor diabetes drugs which have been approved by the FDA to date. We get the following explanation of this increased risk of toe, foot, or leg amputations for Jardiance and Farxiga as well as … [Read more...]
Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations
Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older diabetes drugs such as sulfonylureas, metformin, and thiazolidinediones. This finding was reported in the article “Association Between … [Read more...]
New SGLT2 Inhibitor Diabetes Drugs to Hit the Market in January
Approval On December 19, 2017, the FDA approved Merck & Co. and Pfizer's new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet. These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January. Steglatro consists of ertugliflozin, while Steglujan … [Read more...]
Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
It appears there needs to more medical research done on the risk of lower limb amputations for patients who use the increasing popular diabetes medicines in the sodium glucose cotransporter 2 (SGLT2) inhibitor class, such as canagliflozin (Invokana / Invokamet), empagliflozin (Jardiance / Glyxambi / Synjardy), and dapagliflozin (Farxiga / Xigduo / … [Read more...]
New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance
This article, “SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials”, was published in the October 2017 edition of Diabetologia. It presents the findings of medical researchers who conducted a systematic literature review to identify randomized controlled trials that reported … [Read more...]
SGLT2 Inhibitors May Have an Increased Risk of Acute Renal Failure
SGLT2 Inhibitors: A New Side Effect In previous articles, I have discussed SGLT2 inhibitor diabetes drugs such as Invokana, Farxiga, and Jardiance and the adverse events associated with them. Such side effects include diabetic ketoacidosis (DKA) and lower-limb amputations. A recent study identified a new possible side effect of these drugs … [Read more...]
Rhabdomyolysis May Be Linked To A New Class Of Oral Diabetes Medicines
A class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors may be associated with rhabdomyolysis, a side effect which involves severe muscle damage. In more detail, rhabdomyolysis is the breakdown of muscle tissue that leads to the release of muscle fiber contents into the blood. These substances are harmful to the kidney and … [Read more...]
Could Invokana have been the cause of my lower-limb amputation?
The FDA is investigating a connection between diabetes drugs belonging to the Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors class of drugs and the following side effects: Diabetic Ketoacidosis (DKA) Ketoacidosis Ketosis Acute Kidney Injury Kidney Failure / Renal Failure Kidney Damage Pyelonephritis (kidney infection) … [Read more...]
Can SGLT-2 Inhibitor Diabetes Drugs Increase Your Risk of Stroke?
While we have frequently discussed DKA, kidney damage, and amputations as possible side effects of diabetes drugs in the SGLT-2 inhibitors class -- such as Farxiga, Invokana, Jardiance -- strokes and thromboembolic events are also considered potential harmful effects of these drugs. Based on FAERS reports received during the second quarter of … [Read more...]